CN102639531B - 噻托溴铵的无水合物 - Google Patents

噻托溴铵的无水合物 Download PDF

Info

Publication number
CN102639531B
CN102639531B CN201080044044.4A CN201080044044A CN102639531B CN 102639531 B CN102639531 B CN 102639531B CN 201080044044 A CN201080044044 A CN 201080044044A CN 102639531 B CN102639531 B CN 102639531B
Authority
CN
China
Prior art keywords
tiotropium bromide
anhydrous tiotropium
anhydrous
organic solvent
bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080044044.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102639531A (zh
Inventor
维纳亚克·戈文德·戈雷
宾杜·马诺杰库马
达塔特拉亚·希恩德
达塔特雷·科卡内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN102639531A publication Critical patent/CN102639531A/zh
Application granted granted Critical
Publication of CN102639531B publication Critical patent/CN102639531B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080044044.4A 2009-08-07 2010-08-06 噻托溴铵的无水合物 Expired - Fee Related CN102639531B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1048/KOL/2009 2009-08-07
IN1048KO2009 2009-08-07
PCT/GB2010/051310 WO2011015882A2 (en) 2009-08-07 2010-08-06 Novel anhydrate

Publications (2)

Publication Number Publication Date
CN102639531A CN102639531A (zh) 2012-08-15
CN102639531B true CN102639531B (zh) 2016-01-20

Family

ID=42830336

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080044044.4A Expired - Fee Related CN102639531B (zh) 2009-08-07 2010-08-06 噻托溴铵的无水合物

Country Status (9)

Country Link
US (2) US8697719B2 (enExample)
EP (1) EP2462140A2 (enExample)
JP (2) JP5822831B2 (enExample)
CN (1) CN102639531B (enExample)
AU (1) AU2010280497B2 (enExample)
CA (2) CA2768553C (enExample)
IN (1) IN2012DN00968A (enExample)
NZ (2) NZ597920A (enExample)
WO (1) WO2011015882A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
MX2007009988A (es) * 2005-12-19 2008-02-22 Sicor Inc Formas novedosas de bromuro de tiotropio y procesos para su preparacion.
NZ597920A (en) 2009-08-07 2014-05-30 Generics Uk Ltd Anhydrate of tiotropium bromide
TR201111589A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür susuz kristal formu.
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
CN104341413A (zh) * 2013-07-29 2015-02-11 天津金耀集团有限公司 一种无水噻托溴铵的新晶型
EP2897588B1 (en) * 2013-11-22 2019-07-17 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
EP2913332A1 (en) 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
MX2019004366A (es) * 2016-10-14 2019-08-05 Glenmark Specialty Sa Composiciones nebulizables de tiotropio y formoterol.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861598A (zh) * 2006-03-07 2006-11-15 南昌弘益科技有限公司 噻托溴铵无水物制备方法
CN1875019A (zh) * 2003-11-03 2006-12-06 贝林格尔·英格海姆国际有限公司 具有抗胆碱能的新颖无水晶体
WO2007075858A2 (en) * 2005-12-19 2007-07-05 Sicor Inc. Novel forms of tiotropium bromide and processes for preparation thereof
CN101166738A (zh) * 2005-05-02 2008-04-23 贝林格尔·英格海姆国际有限公司 噻托溴铵的新晶型

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DK1326862T3 (da) 2000-10-12 2004-11-22 Boehringer Ingelheim Pharma Krystallinsk monohydrat af tiotropiumbromid, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE10064816A1 (de) 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums
US6506900B1 (en) 2001-01-31 2003-01-14 Boehringer Ingelheim Pharma Ag Process for preparing a scopine ester intermediate
AUPR315301A0 (en) 2001-02-19 2001-03-15 Silverbrook Research Pty. Ltd. An Apparatus (ART102)
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6610849B2 (en) 2001-06-28 2003-08-26 Boehringer Ingelheim Pharma Kg Process for the manufacture of tropenol
DE10200943A1 (de) 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Scopinestern
US6747153B2 (en) 2002-05-31 2004-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Industrial process for preparing tropenol
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
CN1271073C (zh) * 2004-10-26 2006-08-23 江苏正大天晴药业股份有限公司 结晶性抗胆碱能药噻托溴铵晶体
WO2006076222A2 (en) 2005-01-10 2006-07-20 Glaxo Group Limited Pharmaceutical formulations
KR20080007656A (ko) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 브로마이드의 신규한 결정질 형태
DE102005035112A1 (de) 2005-07-27 2007-02-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Verfahren zur Herstellung von Tiotropiumsalzen unter Anwendung von in organischen Lösungsmitteln löslichen N-Methylscopiniumsalzen
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
MX2007009987A (es) * 2005-12-19 2007-10-02 Sicor Inc Bromuro de tiotropio puro y estable.
US20080051582A1 (en) 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
WO2008089852A1 (de) 2007-01-26 2008-07-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Neues verfahren zur herstellung von tiotropiumsalzen
PT2120936E (pt) 2007-02-21 2011-09-06 Almirall Sa Métodos inovadores
WO2008104955A1 (en) 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
AU2009203579B2 (en) 2008-01-10 2013-07-25 Generics [Uk] Limited Novel process for the preparation of scopine esters
NZ597920A (en) 2009-08-07 2014-05-30 Generics Uk Ltd Anhydrate of tiotropium bromide
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
WO2011015884A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Process to prepare scopine esters
WO2011095800A2 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Analytical methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1875019A (zh) * 2003-11-03 2006-12-06 贝林格尔·英格海姆国际有限公司 具有抗胆碱能的新颖无水晶体
CN101166738A (zh) * 2005-05-02 2008-04-23 贝林格尔·英格海姆国际有限公司 噻托溴铵的新晶型
WO2007075858A2 (en) * 2005-12-19 2007-07-05 Sicor Inc. Novel forms of tiotropium bromide and processes for preparation thereof
CN1861598A (zh) * 2006-03-07 2006-11-15 南昌弘益科技有限公司 噻托溴铵无水物制备方法

Also Published As

Publication number Publication date
AU2010280497A1 (en) 2012-02-23
JP5822831B2 (ja) 2015-11-24
NZ624602A (en) 2015-11-27
US9181268B2 (en) 2015-11-10
US20150051241A9 (en) 2015-02-19
EP2462140A2 (en) 2012-06-13
AU2010280497A8 (en) 2012-03-08
JP2013501041A (ja) 2013-01-10
WO2011015882A2 (en) 2011-02-10
US8697719B2 (en) 2014-04-15
CA2768553A1 (en) 2011-02-10
IN2012DN00968A (enExample) 2015-04-10
NZ597920A (en) 2014-05-30
CA2768553C (en) 2016-08-02
WO2011015882A3 (en) 2011-09-01
US20140249175A1 (en) 2014-09-04
US20120149725A1 (en) 2012-06-14
JP2015214574A (ja) 2015-12-03
CA2931876A1 (en) 2011-02-10
AU2010280497B2 (en) 2015-10-22
CN102639531A (zh) 2012-08-15

Similar Documents

Publication Publication Date Title
CN102639531B (zh) 噻托溴铵的无水合物
CN104797566B (zh) 沃替西汀氢溴酸盐的新结晶形式
CN100586948C (zh) 结晶性抗胆碱能药,其制备方法及其在药物制备中的用途
JP5701246B2 (ja) 有機化合物
ES2396978T3 (es) Forma cristalina novedosa de bromuro de tiotropio y procedimiento para la preparación de la misma
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
JP2023103328A (ja) ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN116987070B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
WO2011015883A1 (en) Dichloromethane solvate of tiotropium bromide and its use
CN101137644A (zh) 7-（2-（4-（3-三氟甲基-苯基）-1,2,3,6-四氢-吡啶-1-基）乙基）异喹啉苯磺酸盐、它的制备与治疗用途
CN117377658A (zh) 喹啉衍生物化合物的制备方法
CN115210210A (zh) 一种(r)-盐酸特布他林的结晶形式
JP6357100B2 (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物
JP2014518236A (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体
WO2002088147A1 (en) Sulfate of cephem compound
CN117561248A (zh) 伊沃替尼和其盐的晶型及其制备方法和用途
BR112020001123B1 (pt) Formas cristalinas inovadoras de trifenatato de vilanterol e processos para sua preparação

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20200806